Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Vivesto AB is a Swedish clinical-stage biopharmaceutical company focused on developing oncology therapeutics, primarily its lead candidate Cantrixil for ovarian cancer treatment. The company has no commercial revenue, operates in pre-commercialization phase, and faces severe financial distress evidenced by 99.8% stock decline over 12 months, negative operating cash flow, and current ratio of 0.38 indicating imminent liquidity crisis. The business model depends entirely on capital raises, partnership deals, or asset sales to fund ongoing clinical trials.
Vivesto operates a high-risk drug development model with no current monetization. The intended path involves advancing Cantrixil through Phase II/III clinical trials for ovarian cancer, securing regulatory approvals (FDA, EMA), then either commercializing directly or out-licensing to larger pharmaceutical partners for upfront payments, milestone payments, and royalties. The company has no pricing power currently and depends on capital markets for survival. Competitive advantage would theoretically derive from differentiated mechanism of action or superior clinical efficacy data, but financial distress suggests clinical progress has not met investor expectations.
Clinical trial data readouts for Cantrixil - efficacy endpoints, safety profile, patient enrollment milestones
Regulatory interactions - FDA/EMA feedback, IND approvals, breakthrough therapy designations
Capital raising announcements - dilutive equity offerings, debt financing, partnership deals with upfront cash
Cash runway updates - quarterly burn rate, months of liquidity remaining given 0.38 current ratio
Competitive landscape changes - rival ovarian cancer therapies advancing or failing in trials
Clinical trial failure risk - Cantrixil may not demonstrate sufficient efficacy or acceptable safety profile in ongoing trials, rendering pipeline value zero
Regulatory approval uncertainty - Even with positive trial data, FDA/EMA approval is not guaranteed; ovarian cancer has high unmet need but also high regulatory scrutiny for survival endpoints
Technological obsolescence - Competing modalities (CAR-T, ADCs, targeted therapies) may render Cantrixil's mechanism non-competitive before commercialization
Large-cap pharma competition - Companies like AstraZeneca (Lynparza), GSK (Zejula) dominate ovarian cancer market with approved PARP inhibitors and established commercial infrastructure
Better-funded clinical-stage competitors with similar indications may reach market first or demonstrate superior data, eliminating partnership interest in Vivesto's assets
Imminent liquidity crisis - 0.38 current ratio indicates inability to cover short-term obligations; company likely requires immediate capital raise to avoid insolvency
Severe dilution risk - Equity raises at 99% depressed stock price would massively dilute existing shareholders; death spiral financing risk if forced to raise at distressed valuations
Going concern uncertainty - Auditors likely flagged substantial doubt about ability to continue operations given cash burn and lack of revenue
moderate - While drug demand is non-cyclical, clinical-stage biotechs face cyclical capital availability. During economic contractions, risk capital for speculative biotech diminishes, making financing rounds more difficult or dilutive. Institutional appetite for high-risk, pre-revenue assets correlates with broader risk-on sentiment. However, oncology drug development timelines are independent of GDP cycles.
High sensitivity through multiple channels: (1) Rising rates increase discount rates applied to distant future cash flows, disproportionately hurting long-duration assets like clinical-stage biotechs with 5-10 year commercialization timelines. (2) Higher rates make safer fixed-income alternatives more attractive, reducing speculative capital flows into biotech. (3) Increased cost of debt financing if company pursues non-dilutive capital. The 99% stock decline coincides with 2022-2025 rate hiking cycle, suggesting valuation compression from higher discount rates.
Critical - Company's survival depends on accessing capital markets for equity or debt financing. Credit market tightening (widening high-yield spreads) reduces financing options and increases dilution risk for equity raises. With 0.38 current ratio and negative cash flow, inability to access credit markets would force asset liquidation or bankruptcy. Investment-grade credit conditions are irrelevant; company would access high-risk venture debt or dilutive equity only.
Speculative growth - Only extremely high-risk tolerance investors (venture capital, biotech-focused hedge funds, retail speculators) would consider given 99.8% decline and pre-revenue status. This is a binary outcome investment: either clinical success leads to 10x+ recovery or company liquidates with total loss. No value, dividend, or momentum investors would participate. Current holders likely include distressed debt specialists or those averaging down on sunk costs.
extreme - Stock exhibits massive volatility typical of clinical-stage biotechs with binary catalysts. 99% drawdown indicates either catastrophic clinical news, financing failure, or both. Beta likely exceeds 2.0 relative to biotech indices. Daily moves of 20-50% common around trial data releases or financing announcements.
